NAD+

NAD+ IV therapy traditionally has been used to treat patients suffering from various mental illnesses and psychological disorder. However, NAD+ possesses potential benefits to function as a synergistic treatment for those suffering from the lung disease idiopathic pulmonary fibrosis.

COVID-19 patients have exhibited overactive PARP-1 enzymes and dysregulated T-cells. These inappropriate immune responses have been linked to an exacerbation of symptom severity and higher prevalence of long COVID. . Experts have suggested that NAD+ can serve as a successful PARP-1 inhibitor and T-cell regulator, highlighting NAD+ as a perfect candidate for the treatment of COVID-19 and prevention of long COVID.